AstraZeneca completes respiratory deal with Actavis
March 3, 2015Research and Development, Sales and Marketing Actavis, AstraZeneca, COPD, Daliresp, Tudorza Pressair, aclidinium bromide inhalation powder, respiratory, roflumilast
AstraZeneca has completed its acquisition of Dublin-headquartered firm Actavis with its branded respiratory portfolio deal worth $700 million. The agreement …
Boehringer chases approval for anti-Pradaxa drug
March 3, 2015Sales and Marketing Boehringer, Boehringer Ingelheim, Pradaxa, bleeding, dabigatran etexilate, idarucizumab
Boehringer Ingelheim is launching new drug applications for its investigational treatment to reverse the effects of its blood-thinning drug Pradaxa. …
Takeda expands in Singapore
March 3, 2015Manufacturing and Production Singapore, Takeda, biopolis, emerging markets, vaccines
Japanese pharma giant Takeda has set up new Singapore offices in the Biopolis biomedical complex with the aim of expanding …
Chiesi reprimanded again over Fostair drug
March 3, 2015Manufacturing and Production, Medical Communications, Sales and Marketing ABPI, Chiesi, PMCPA, code, formoterol/beclometason, fostair
Chiesi has been reprimanded after it breached the ABPI’s Code of Practice for its promotion of asthma inhaler Fostair. The …
NICE recommends Harvoni for hepatitis C
March 3, 2015Sales and Marketing Gilead, NICE, harvoni, hepatitis C, ledipasvir-sofosbuvir
NICE has signalled a provisional OK for Gilead’s Harvoni to be used as a treatment for hepatitis C by the …
Premise Health senior joins Nashville Health Care Council
March 3, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing nashville health care council, premise health
US worksite health and patient engagement firm Premise Health has announced that its senior VP Beth Ratliff has been selected …
ZMapp trials start in Liberia
March 2, 2015Research and Development, Sales and Marketing Africa, Ebola, Mapp, Vaccine, liberia, zmapp
Clinical trials to test the safety and efficacy of the experimental Ebola vaccine ZMapp are underway in infected parts of …
Eisai launches Lenvima in US
March 2, 2015Sales and Marketing FDA, Japan, Lenvima, US, dtc, thyroid
Japanese firm Eisai has launched its new thyroid cancer offering Lenvima in the US, making it the first country in …
Three drugs put forward for EMA authorisation
March 2, 2015Research and Development, Sales and Marketing Amgen, EMA, FDA, Novartis, Otsuka, jinarc, ristempa, zykadia
Novartis’ lung cancer drug Zykadia has been recommended for EU approval in patients previously treated with Pfizer’s Xalkori – the …
23andMe appoints privacy officer
March 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 23andME, kate black
US genetics testing firm 23andMe has appointed Kate Black as its privacy officer and corporate counsel.
Precision medicine: the future of cancer treatment?
March 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cancer, Celgene, Precision, melanoma, oncology, underwood
There are plenty of advances in oncology treatments to be excited about – from immunotherapy to cancer vaccines and monoclonal …
GSK and Novartis swap assets
March 1, 2015Research and Development, Sales and Marketing GSK, Mencevax, Nimenrix, Novartis, akt, merger, oncology, vaccines
GlaxoSmithKline’s planned major assets swap with Novartis has completed today as was predicted last week. Both firms announced the overhaul …
New EU indication for Bayer and Regeneron eye drug
February 27, 2015Sales and Marketing Bayer, European Commission, Eylea, aflibercept
Bayer and Regeneron’s Eylea is now indicated for every type of the eye disease retinal vein occlusion (RVO) thanks to …
Ousted Sanofi boss finds role at PureTech
February 27, 2015Sales and Marketing Bayer, Sanofi, Viehbacher, baumann, brandicourt, pott, puretech
US science and technology R&D company PureTech has appointed the former Sanofi chief executive Christopher Viehbacher to its board. Viehbacher …
Actavis and AZ see FDA approval for ‘superbug’ drug
February 27, 2015Research and Development, Sales and Marketing Actavis, AstraZeneca, Avycaz, FDA, US, ceftazidime/avibactam
Actavis and AstraZeneca’s combo ‘superbug’ drug Avycaz has been shown the green light to treat patients with complicated intra-abdominal infections …
Bayer justifies Brandicourt’s ‘golden handshake’
February 27, 2015Medical Communications, Sales and Marketing Bayer, CEO, Sanofi, dekkers, olivier brandicourt, payments, wages
Bayer has confirmed that Sanofi’s justification for the controversial starter package it is giving to the German firm’s Olivier Brandicourt …
Most Americans ready for health wearables and apps
February 27, 2015Medical Communications, Sales and Marketing Makovsky/Kelton, Pulse of Online Health, US, app, apps, digital, wearables
Americans are ready and willing to leverage health apps and wearable devices in order to improve their personal health according …
Bayer MaterialScience gets new chairman
February 27, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Oliver Brandicourt, Werner Baumann, richard pott
Dr Richard Pott has been appointed to the supervisory board at Bayer MaterialScience as its new chairman. Pott replaces Werner …
GlaxoSmithKline announces board changes early
February 26, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, GlaxoSmithKline, Tom de Swaan, christopher gent, sir philip hampton
GlaxoSmithKline has confirmed that Sir Christopher Gent will step down early as chairman of GSK in May to be succeeded …
New drugs give Bayer record sales
February 26, 2015Sales and Marketing Bayer, Eylea, Radium-223 chloride, Stivarga, Xarelto, adempas, aflibercept, dekkers, german, regorafenib, riociguat, xofigo
Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
